Peptidoglycan is an indispensable component of bacterial cell walls. We recently discovered an alternative peptidoglycan biosynthetic pathway, which involves two enzymes, MurD2 and MurL, catalyzing the ligation of L-Glu to UDP-MurNAc-L-Ala and epimerization of the terminal L-Glu of the MurD2 product, respectively. Because the pathway operates in Xanthomonas oryze, a pathogen causing bacterial blight of rice, we searched for specific inhibitors from metabolites produced by actinomycetes to obtain a lead compound to function as an agrochemical. Actinomycin D was isolated from Streptomyces parvulus NBRC 13193 as a specific inhibitor of the pathway. In vitro analysis indicated that actinomycin D inhibited the MurD2 reaction.
Peptidoglycan is a component of bacterial cell walls and is important for the survival of bacteria. The structure of peptidoglycan contains linear glycan strands with alternating N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) and the glycan strands are cross-linked to each other with oligopeptides to form a 3D mesh-like layer. The biosynthesis of peptidoglycan has been well studied and the early steps require four ATP-grasp enzymes, MurC, MurD, MurE, and MurF, to biosynthesize UDP-MurNAcpentapeptide in which the carboxyl group of UDP-MurNAc is attached to a pentapeptide of L-alanine (L-Ala)-D-glutamic acid (D-Glu)-diamino acid (meso-diaminopimelic acid or L-lysine)-D-Ala-D-Ala ( Fig. 1 , pathway A: canonical pathway) [1, 2] . In this canonical process, MurD ligates D-Glu to the carboxylic acid of UDP-MurNAc-L-Ala (1) to yield UDP-MurNAc-L-Ala-D-Glu (2), and the D-Glu used for this reaction is generally supplied by a glutamate racemase, MurI. However, we recently identified an alternative biosynthetic pathway operating in some bacteria including the genus Xanthomomas, which are plant pathogens (3) . In this pathway, MurD2, which has homology to MurD, ligates L-Glu with 1 to generate UDP-MurNAc-L-Ala-L-Glu [3] and the subsequent epimerization catalyzed by MurL yields 2 ( Fig. 1 , pathway B: alternative pathway). We showed that subtle amino acid substitutions in the active site in MurD/MurD2 resulted in a difference in the stereochemical recognition of Glu substrates [4] . Because peptidoglycan biosynthesis is essential for the survival of microorganisms, and most bacteria employ the canonical pathway, MurD2 and MurL are attractive targets for the development of specific anti-Xanthomonas agrochemicals. Furthermore, inhibitors of these enzyme would be useful to investigate the detailed reaction mechanisms of these enzymes. In this study, we searched for metabolites inhibiting the alternative peptidoglycan biosynthetic pathway from a culture broth library of actinomycetes and identified actinomycin D as a specific inhibitor.
To identify specific inhibitors of the alternative peptidoglycan biosynthesis efficiently, we developed a paper disk-agar diffusion assay using two actinomycete strains, Micromonospora sp. ATCC 39149 and Streptomyces lividans TK23, as the test microorganisms. Both strains belong to the phylum Actinobacteria and are similar to each other in terms of genome size, G+C content, and 16S rDNA * Yasushi Ogasawara yogasawa@eng.hokudai.ac.jp * Tohru Dairi dairi@eng.hokudai.ac.jp 1 Graduate School of Engineering, Hokkaido University, Sapporo, Hokkaido 060-8628, Japan sequence. However, the Micromonospora strain employs the alternative pathway in peptidoglycan biosynthesis while the Streptomyces strain employs the canonical pathway [3] . Consequently, compounds that inhibit the enzymes in the alternative pathway would specifically suppress the growth of the Micromonospora strain. We tested approximately 200 actinomycetes culture broths. Of these, one sample (Streptomyces parvulus NBRC 13193 culture broth) specifically inhibited the growth of Micromonospora sp. In addition, this sample also inhibited the growth of Xanthomonas oryzae. We thus speculated that this sample contained a compound that specifically inhibited the alternative pathway of peptidoglycan biosynthesis and we performed in vitro inhibition assays of MurD2 and MurL reactions using recombinant enzymes. However, all attempts to perform the inhibition assay using the crude culture broth failed, probably because of the low content of an active component in the sample. Hence, we first purified the active component on a small scale using a HPLC system equipped with a C-18 column, and a bioactive fraction eluted at a retention time of 14 min was subjected to the in vitro inhibition assay (Figs. S1 and S2). This sample was found to inhibit the MurD2 reaction, indicating that the active component in the culture broth inhibited the alternative pathway of peptidoglycan biosynthesis.
To purify the active component in the culture broth, S. parvulus NBRC 13193 was cultivated in a 100-ml test tube containing 10 ml of TSB medium on a rotary shaker (200 rpm) at 30°C for 3 days. A portion of the seed culture (1 ml) was transferred into a 200-ml Erlenmeyer flask containing 40 ml of modified SK No. 2 medium (2% soluble starch, 0.5% glucose, 0.5% yeast extract, 0.3% Bacto peptone, 0.3% Kyokuto fish extract (paste), 0.02% KH 2 PO 4 , and 0.06% MgSO 4 ·7H 2 O, to pH 7.6 with NaOH, in a total volume of 2 l) and cultivated on a rotary shaker (200 rpm) at 30°C for 5 days. After removing the cells by centrifugation, the supernatant was extracted with the same volume of ethyl acetate, at neutral pH, three times. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was further purified using silica gel flash column chromatography using ethyl acetate as the eluent. The bioactive fractions were collected and evaporated in vacuo to yield compound 4 as a red solid. The high resolution ESI-MS and 13 C NMR spectra of 4 indicated that its molecular formula was C 62 H 86 N 12 O 16 ([M+H] + calculated for C 62 H 87 N 12 O 16 : 1255.6358; found: 1255.6373). To elucidate the structure, single crystals of 4 were grown from its methanol solution by vapor diffusion of wet ethanol. Compound 4 crystallized, in a similar fashion to the previously reported crystal structure of actinomycin D, with the triclinic space group P1 with three molecules of 4 in the asymmetric unit [5] . The amino acid sequence (L-Thr, D-Val, L-Pro, sarcosine, L-Me-Val) for the macrocycles and their stereochemistry were unambiguously confirmed by the crystal structure. Together with 1D ( 1 H and 13 C) and 2D (COSY, TOCSY, HSQC, HMBC, and band-selective HMBC) NMR resonances, compound 4 was revealed to be actinomycin D (Fig. 2,  Figs. S3-15 , Table. S1) [6] [7] [8] .
Actinomycin D, also known as dactinomycin, is the first antibiotic that demonstrated anticancer activity and was approved for medical use by the Food and Drug Administration (FDA) in 1964. It inhibits RNA synthesis as a result of its ability to bind DNA at the transcription initiation complex, with specificity favoring the 5ʹ-GC-3ʹ sequence [9, 10] . Several Streptomyces strains produce actinomycin D, and S. parvulus NBRC 13193 is one such strain. Because actinomycin D was previously reported to exhibit antimicrobial activity against Gram-positive bacteria but not against Gram-negative bacteria [6] , we carried out a growth inhibition assay using commercially available actinomycin D against a panel of bacteria. Actinomycin D was active against Gram-negative X. oryzae and Gram-positive Micromonospora sp. but not against Gram-negative Escherichia coli and Pseudomonas strains and Gram-positive S. lividans. The minimum inhibition concentration (MIC) against X. oryzae was determined to be 25 μM, while the MIC values against other Gramnegative bacteria (E. coli XL1 Blue, Pseudomonas putida, and Pseudomonas syringae) were calculated to be >1 mM. Furthermore, an in vitro inhibition assay revealed that actinomycin D inhibited the MurD2 reaction ( Fig. S2) .
We next determined the inhibition constants of 4 for MurD2. Because kinetic analysis of MurD2 has never been reported, we first determined the Michaelis constant of MurD2 by varying the concentration of one of three substrates, UDP-MurNAc-L-Ala, L-Glu, or ATP. The MurD2 reaction followed Michaelis-Menten kinetics and the K m values for 1, L-Glu, and ATP were 1.0 mM, 2.4 mM, and 0.27 mM, respectively and the k cat value was 1 × 10 3 min −1 (Fig. S16) . The inhibition constants of actinomycin D against MurD2 were determined graphically from Dixon plots by varying the concentrations of actinomycin D (0, 0.5, 1.0, and 2.0 mM) and one of three substrates (two different concentrations above and below the K m value). Apparent K i values for 1, L-Glu, and ATP were 0.46 mM, 1.9 mM, and 2.8 mM, respectively (Fig. S17 ).
In conclusion, we showed that actinomycin D is an inhibitor of the alternative pathway of peptidoglycan biosynthesis for the first time. In vitro analysis revealed that actinomycin D inhibited the MurD2 reaction. Our findings may be useful in the design of more potent inhibitors of the alternative pathway of peptidoglycan biosynthesis.
